Autoimmune Diseases  >>  opicinumab (BIIB033)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
opicinumab (BIIB033) / Biogen
SYNERGY, NCT01864148 / 2011-006262-40: Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Checkmark SYNERGY trial in RRMS
Sep 2016 - Sep 2016: SYNERGY trial in RRMS
Hourglass Sep 2016 - Sep 2016 : Presentation from the SYNERGY study at ECTRIMS
Checkmark SYNERGY trial
Jun 2016 - Jun 2016: SYNERGY trial
More
Completed
2
419
US, Canada, Europe, RoW
BIIB033, anti-LINGO-1 mAb, Placebo, Avonex, interferon beta-1a
Biogen
Multiple Sclerosis
12/15
03/16

Download Options